Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma

Published:2020-06-10 Issue:8 Volume:40 Page:1800-1811
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Rimassa Lorenza¹²^ORCID,Wörns Marcus‐Alexander³^ORCID

Affiliation:

1. Medical Oncology and Hematology Unit Humanitas Cancer Center Humanitas Clinical and Research Center – IRCCS Milan Italy

2. Department of Biomedical Sciences Humanitas University Milan Italy

3. Department of Internal Medicine I/Cirrhosis Center Mainz (CCM) University Medical Center of the Johannes Gutenberg‐University Mainz Germany

Funder

Ipsen Fund

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14533

Reference82 articles.

1. World Cancer Research Fund.Liver cancer. How diet nutrition and physical activity affect liver cancer risk.https://www.wcrf.org/dietandcancer/liver‐cancer. Accessed January 2020

2. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

3. Hepatocellular carcinoma

4. Chemotherapy for hepatocellular carcinoma: The present and the future

5. European Medicines Association (EMA).Sorafenib (Nexavar). Summary of product characteristics.https://www.ema.europa.eu/en/documents/product‐information/nexavar‐epar‐product‐information_en.pdf. Accessed January 2020

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States;Cancers;2023-11-22

2. Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma;Therapeutics and Clinical Risk Management;2023-04

3. Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future;European Journal of Cell Biology;2023-03

4. Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects;Purinergic Signalling;2023-02-13

5. Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study;BMC Cancer;2023-01-19